Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer

Lassen Therapeutics, a biotech that is developing antibodies as potential treatments for fibrosis, rare diseases, and cancer, debuted Wednesday with $31 million in Series A financing.